Big Pharmas Come Together On TB, But Effort To Accelerate Development May Hit Speedbump From Lack Of Biomarkers
This article was originally published in Pharmaceutical Approvals Monthly
A new multi-pharma company collaboration is intended to dramatically speed development of new combination regimens for tuberculosis, but efforts to accelerate development may be hindered by the lack of biomarkers for TB
You may also be interested in...
FDA is developing guidances -both in general and for specific therapeutic areas - for co-development of investigational drugs intended to be used in combination, and the move is indeed timely.